Pharmaceuticals, Biotechnology & Life Sciences

Corporate governance overhaul: new independent directors, BSE/NSE migration, and secure remote e‑voting promise higher transparency, lower cost of capital, but also new compliance challenges and short‑term volatility.

Incyte’s new Phase‑II/III data shows INCA033989 and tafasitamab + lenalidomide + R‑CHOP significantly improve outcomes for myelofibrosis, ET and high‑risk B‑cell lymphoma, offering promising efficacy, safety, and competitive pricing for payers and p…

Genmab’s epcoritamab shows 78‑92% response rates in elderly DLBCL patients, offering a safe, cost‑effective outpatient alternative to anthracycline or CAR‑T therapies, with strong market and reimbursement potential.

Insmed’s removal from the NASDAQ‑100 amid AI and semiconductor additions shows how passive funds shift capital toward high‑growth tech, yet the company’s fundamentals stay strong.

Incyte’s Phase III frontMIND data show tafasitamab + lenalidomide boosts PFS in high‑risk DLBCL, driving a 12% revenue CAGR, strong margins, and new value‑based reimbursement opportunities.

Explore why Mettler‑Toledo’s share price fell 19% in the last 5 years, the risks of regulatory hurdles, and hidden growth in digital twins and emerging markets – find your investment edge now.

GSK’s momelotinib earns orphan drug status for VEXAS syndrome, paving the way for the ATLAS trial and positioning a first‑in‑class JAK inhibitor in a market with no current therapies.

AbbVie’s CLL14 Phase III results show venetoclax‑obinutuzumab gives eight‑year disease control with fewer side‑effects, reshaping first‑line CLL care.

Merck KGaA’s 2.5% share dip mirrors DAX stability while highlighting its pivotal role in the growing in‑vitro toxicology market—driven by regulatory shifts, tech innovation, and pharma demand.

Pfizer’s new HYMPAVZI approval and Seagen‑Metsera acquisitions show a strategic shift toward rare‑disease, oncology, and obesity markets, boosting long‑term growth potential.